All In Biotech

Investigational drug · Phase 3

Povetacicept

Also called: ALPN-303

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

6 still active

All registered trials

8

Any phase or sponsor naming "Povetacicept"

First trial start

2023

Mar 15, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Povetacicept", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Immunoglobulin A Nephropathy
  • Myasthenia Gravis, Generalized
  • Primary Membranous Nephropathy
  • Lupus Nephritis
  • Membranous Nephropathy
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Idiopathic Thrombocytopenic Purpura
  • Immune Thrombocytopenia
  • Warm Autoimmune Hemolytic Anemia
  • Cold Agglutinin Disease

Approved drugs for the same conditions: Anemia · Immune thrombocytopenia · Myasthenia gravis · Lupus (SLE) · IgA nephropathy · Hematology and blood cancers · Cardiovascular and metabolic · Neurology · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Povetacicept" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 13 on PubMed

Also in development for Immunoglobulin A Nephropathy

  • FelzartamabPhase 38 trials

    Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease

  • FUB523zigakibart, BION-1301Phase 36 trials

    Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)

  • Alpine Immune Sciences Inc, A Subsidiary of Vertex · Immunoglobulin A Nephropathy

  • MIL116Phase 21 trial

    Beijing Mabworks Biotech Co., Ltd. · Immunoglobulin A Nephropathy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.